Menu
Back to Journals » Drug Design, Development and Therapy » Volume 19
RET Inhibitor SPP86 is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Response to Letter]
Yuli Zhang,1,2 Haidong Liu,1 Kun Wang,3 Juan Zheng,4 Hong Luan,1 Ming Xin5
1Department of Dermatology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China; 2Department of Endocrinology, The Second Hospital of Shandong University, Jinan, Shandong, People’s Republic of China; 3Department of Endocrinology and Metabology, Liaocheng, People’s Hospital, Liaocheng, Liaocheng, Shandong, People’s Republic of China; 4Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China; 5The Key Laboratory of Molecular Pharmacology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China
Correspondence: Ming Xin, The Key Laboratory of Molecular Pharmacology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China, Email [email protected] Hong Luan, Department of Dermatology, Liaocheng People’s Hospital, Liaocheng, Shandong, People’s Republic of China, Email [email protected]
View the original paper by Dr Zhang and colleagues
This is in response to the Letter to the Editor
Dear editors
Thank you very much for your interest in our research and for your valuable feedback. We are grateful for your positive comments and appreciate the constructive suggestions you provided. Your input is essential to further improving our study.
Regarding your suggestion for in vivo experimental validation, we wholeheartedly agree and are actively pursuing related research. In fact, our team has already secured research funding and initiated in vivo experiments using a mouse melanoma model to assess the anti-tumor effects of SPP86. Upon completion of these experiments, we intend to publish the results as a separate paper, and we hope you will look forward to it.
We are also very interested in your suggestion to explore “synthetic lethality as a therapeutic strategy” and the potential of combining SPP86 with PARP1 inhibitors (eg, olaparib). We greatly appreciate this insightful recommendation, and it is an avenue we plan to explore in future studies.
Finally, we acknowledge that clinical treatment for melanoma remains a complex challenge. Our research in this area is ongoing, and we will continue working towards advancing our understanding and contributing to more effective therapeutic options for melanoma treatment.
Disclosure
The authors declare that there are no conflicts of interest in this communication.
© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.